Advertisement
Survey:
1 / 2
(Bloomberg) — The rapid selloff in Tesla Inc. shares has left most price targets from ever-bullish Wall Street analysts seemingly obsolete.
Most Read from Bloomberg
Malaysia Latest: King to Interview Lawmakers to Determine New PM
Swedish Housing Is Now in the Worst Rout Since the 1990s
Disney Shares Jump on Optimism Over Iger’s Surprise Return
Crypto Brokerage Genesis Is Said to Warn of Bankruptcy Without Funding
Beyond Meat Plant’s Dirty Conditions Revealed in Photos, Documents
The yawning gap means Tesla shares need to rally a whopping 80% to hit the median analyst target price — the second widest on the Nasdaq 100 Index, just behind Baidu Inc. The Elon Musk-led firm’s stock has slumped 52% this year to $167.87, while analysts have a median 12-month target price of $302.
Tesla has been facing a host of issues including Musk’s shift-in-focus on turning around Twitter Inc. to China’s return to Covid Zero curbs. Adding to that are supply-chain snarls, rising raw-material costs and buyers feeling the squeeze of stubborn inflation and rising interest rates.
Still, many analysts are sticking to their bullish calls, with 27 of them rating the stock a buy, while 11 have a hold and seven have sell. The most bullish call has a price target of $530, according to data compiled by Bloomberg.
“It could be very hard for the stock to recover in the coming years,” said Valerie Gastaldy, a technical analyst at DaybyDay. “We recommend not looking back and waving bye-bye to this old darling.”
The slump this year has taken Tesla’s market capitalization to a touch above $530 billion, a far cry from a trillion dollars in April.
Most Read from Bloomberg Businessweek
Tech Layoffs Send H-1B Visa Holders Scrambling for New Jobs
Sears Limps Through What Could Be Its Final Holiday Season
A Nation in the Crosshairs of Climate Change Is Ready to Get Rich on Oil
How to Make Your Company Accessible for Disabled Employees
Fatal Crashes Highlight Rising Danger of Illicit Charter Flights
©2022 Bloomberg L.P.
Advertisement
Comments